Effects of Vitamin D supplementation on markers of vascular function after myocardial infarction

A randomised controlled trial

Miles D. Witham (Lead / Corresponding author), Fiona J. Dove, Faisel Khan, Chim C. Lang, Jill J. F. Belch, Allan D. Struthers

    Research output: Contribution to journalArticle

    45 Citations (Scopus)

    Abstract

    BACKGROUND: Low vitamin D levels are common, and are associated with a higher incidence of future vascular events. We tested whether vitamin D supplementation could improve endothelial function and other markers of vascular function in patients with a history of myocardial infarction. METHODS: Parallel group, placebo-controlled, double-blind randomised trial. Patients with a history of myocardial infarction were randomised to receive 100,000 units of oral vitamin D3 or placebo at baseline, 2months and 4months. Outcomes were measured at baseline, 2 and 6months. Reactive hyperaemia index on fingertip plethysmography was the primary outcome. Secondary outcome measures included blood pressure, cholesterol, C-reactive protein, von Willebrand factor, tumour necrosis factor alpha, E-selectin, B-type natriuretic peptide, thrombomodulin and 25-hydroxyvitamin D levels. RESULTS: 75 patients were randomised, mean age 66years. 74/75 (99%) completed 6month follow-up. 25 hydroxyvitamin D levels increased in the intervention group relative to placebo (+13 vs +1nmol/L, p=0.04). There was no between-group difference in change in reactive hyperaemia index between baseline and 6months (-0.18 vs -0.07, p=0.40). Of the secondary outcomes, only C-reactive protein showed a significant decline in the intervention arm relative to placebo at 6months (-1.3 vs 2.0mg/L, p=0.03). Systolic blood pressure (+1.4 vs +2.3mmHg, p=0.79), diastolic blood pressure (+2.0 vs +0.8mmHg, p=0.54) and total cholesterol (+0.26 vs +0.24mmol/L, p=0.88) showed no between-group difference at 6months. CONCLUSIONS: Supplementation with vitamin D did not improve markers of vascular function in patients with a history of myocardial infarction.
    Original languageEnglish
    Pages (from-to)745-749
    Number of pages5
    JournalInternational journal of cardiology
    Volume167
    Issue number3
    DOIs
    Publication statusPublished - 10 Aug 2013

    Fingerprint

    Vitamin D
    Blood Vessels
    Randomized Controlled Trials
    Myocardial Infarction
    Blood Pressure
    Placebos
    Hyperemia
    C-Reactive Protein
    Cholesterol
    Thrombomodulin
    E-Selectin
    Plethysmography
    Cholecalciferol
    Brain Natriuretic Peptide
    von Willebrand Factor
    Tumor Necrosis Factor-alpha
    Outcome Assessment (Health Care)
    Incidence
    25-hydroxyvitamin D

    Cite this

    @article{7f980cef9bbd43939994eddbf9d53079,
    title = "Effects of Vitamin D supplementation on markers of vascular function after myocardial infarction: A randomised controlled trial",
    abstract = "BACKGROUND: Low vitamin D levels are common, and are associated with a higher incidence of future vascular events. We tested whether vitamin D supplementation could improve endothelial function and other markers of vascular function in patients with a history of myocardial infarction. METHODS: Parallel group, placebo-controlled, double-blind randomised trial. Patients with a history of myocardial infarction were randomised to receive 100,000 units of oral vitamin D3 or placebo at baseline, 2months and 4months. Outcomes were measured at baseline, 2 and 6months. Reactive hyperaemia index on fingertip plethysmography was the primary outcome. Secondary outcome measures included blood pressure, cholesterol, C-reactive protein, von Willebrand factor, tumour necrosis factor alpha, E-selectin, B-type natriuretic peptide, thrombomodulin and 25-hydroxyvitamin D levels. RESULTS: 75 patients were randomised, mean age 66years. 74/75 (99{\%}) completed 6month follow-up. 25 hydroxyvitamin D levels increased in the intervention group relative to placebo (+13 vs +1nmol/L, p=0.04). There was no between-group difference in change in reactive hyperaemia index between baseline and 6months (-0.18 vs -0.07, p=0.40). Of the secondary outcomes, only C-reactive protein showed a significant decline in the intervention arm relative to placebo at 6months (-1.3 vs 2.0mg/L, p=0.03). Systolic blood pressure (+1.4 vs +2.3mmHg, p=0.79), diastolic blood pressure (+2.0 vs +0.8mmHg, p=0.54) and total cholesterol (+0.26 vs +0.24mmol/L, p=0.88) showed no between-group difference at 6months. CONCLUSIONS: Supplementation with vitamin D did not improve markers of vascular function in patients with a history of myocardial infarction.",
    author = "Witham, {Miles D.} and Dove, {Fiona J.} and Faisel Khan and Lang, {Chim C.} and Belch, {Jill J. F.} and Struthers, {Allan D.}",
    note = "Copyright {\circledC} 2012 Elsevier Ireland Ltd. All rights reserved.",
    year = "2013",
    month = "8",
    day = "10",
    doi = "10.1016/j.ijcard.2012.03.054",
    language = "English",
    volume = "167",
    pages = "745--749",
    journal = "International journal of cardiology",
    issn = "0167-5273",
    publisher = "Elsevier",
    number = "3",

    }

    TY - JOUR

    T1 - Effects of Vitamin D supplementation on markers of vascular function after myocardial infarction

    T2 - A randomised controlled trial

    AU - Witham, Miles D.

    AU - Dove, Fiona J.

    AU - Khan, Faisel

    AU - Lang, Chim C.

    AU - Belch, Jill J. F.

    AU - Struthers, Allan D.

    N1 - Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

    PY - 2013/8/10

    Y1 - 2013/8/10

    N2 - BACKGROUND: Low vitamin D levels are common, and are associated with a higher incidence of future vascular events. We tested whether vitamin D supplementation could improve endothelial function and other markers of vascular function in patients with a history of myocardial infarction. METHODS: Parallel group, placebo-controlled, double-blind randomised trial. Patients with a history of myocardial infarction were randomised to receive 100,000 units of oral vitamin D3 or placebo at baseline, 2months and 4months. Outcomes were measured at baseline, 2 and 6months. Reactive hyperaemia index on fingertip plethysmography was the primary outcome. Secondary outcome measures included blood pressure, cholesterol, C-reactive protein, von Willebrand factor, tumour necrosis factor alpha, E-selectin, B-type natriuretic peptide, thrombomodulin and 25-hydroxyvitamin D levels. RESULTS: 75 patients were randomised, mean age 66years. 74/75 (99%) completed 6month follow-up. 25 hydroxyvitamin D levels increased in the intervention group relative to placebo (+13 vs +1nmol/L, p=0.04). There was no between-group difference in change in reactive hyperaemia index between baseline and 6months (-0.18 vs -0.07, p=0.40). Of the secondary outcomes, only C-reactive protein showed a significant decline in the intervention arm relative to placebo at 6months (-1.3 vs 2.0mg/L, p=0.03). Systolic blood pressure (+1.4 vs +2.3mmHg, p=0.79), diastolic blood pressure (+2.0 vs +0.8mmHg, p=0.54) and total cholesterol (+0.26 vs +0.24mmol/L, p=0.88) showed no between-group difference at 6months. CONCLUSIONS: Supplementation with vitamin D did not improve markers of vascular function in patients with a history of myocardial infarction.

    AB - BACKGROUND: Low vitamin D levels are common, and are associated with a higher incidence of future vascular events. We tested whether vitamin D supplementation could improve endothelial function and other markers of vascular function in patients with a history of myocardial infarction. METHODS: Parallel group, placebo-controlled, double-blind randomised trial. Patients with a history of myocardial infarction were randomised to receive 100,000 units of oral vitamin D3 or placebo at baseline, 2months and 4months. Outcomes were measured at baseline, 2 and 6months. Reactive hyperaemia index on fingertip plethysmography was the primary outcome. Secondary outcome measures included blood pressure, cholesterol, C-reactive protein, von Willebrand factor, tumour necrosis factor alpha, E-selectin, B-type natriuretic peptide, thrombomodulin and 25-hydroxyvitamin D levels. RESULTS: 75 patients were randomised, mean age 66years. 74/75 (99%) completed 6month follow-up. 25 hydroxyvitamin D levels increased in the intervention group relative to placebo (+13 vs +1nmol/L, p=0.04). There was no between-group difference in change in reactive hyperaemia index between baseline and 6months (-0.18 vs -0.07, p=0.40). Of the secondary outcomes, only C-reactive protein showed a significant decline in the intervention arm relative to placebo at 6months (-1.3 vs 2.0mg/L, p=0.03). Systolic blood pressure (+1.4 vs +2.3mmHg, p=0.79), diastolic blood pressure (+2.0 vs +0.8mmHg, p=0.54) and total cholesterol (+0.26 vs +0.24mmol/L, p=0.88) showed no between-group difference at 6months. CONCLUSIONS: Supplementation with vitamin D did not improve markers of vascular function in patients with a history of myocardial infarction.

    UR - http://www.scopus.com/inward/record.url?scp=84880922748&partnerID=8YFLogxK

    U2 - 10.1016/j.ijcard.2012.03.054

    DO - 10.1016/j.ijcard.2012.03.054

    M3 - Article

    VL - 167

    SP - 745

    EP - 749

    JO - International journal of cardiology

    JF - International journal of cardiology

    SN - 0167-5273

    IS - 3

    ER -